Syros Pharmaceuticals,Inc. (NASDAQ:SYRS) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition. |
Although it has not finalized its full financial results for the
fourth quarter and fiscal year ended December31, 2016, the
Company announced on January9, 2017, that it expects to report
that it had more than $83 million in cash, cash equivalents and
marketable securities as of December31, 2016.
The information contained in Item2.02 of this Form8-K is
unaudited and preliminary, and does not present all information
necessary for an understanding of the Companys financial
condition as of December31, 2016 and its results of operations
for the three months and year ended December31, 2016. The audit
of the Companys consolidated financial statements for the year
ended December31, 2016 has not yet commenced and this audit could
result in changes to the information set forth above.
The information in this Item2.02 shall not be deemed filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act) or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
|
Item8.01 |
Other Events. |
On January9, 2017, the Company issued a press release announcing
its 2017 business goals and financial guidance. The full text of
this press release is filed as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference.
|
Item9.01 |
Financial Statements and Exhibits. |
|
(d) |
The following exhibits are included in this report: |
|
Ress Reles |
|
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated January9, 2017 |
2
About Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients. Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Recent Trading Information
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) closed its last trading session down -1.07 at 12.00 with 12,541 shares trading hands.
